Skip to main content
. Author manuscript; available in PMC: 2024 Feb 20.
Published in final edited form as: J Hepatol. 2018 Dec 14;70(4):700–709. doi: 10.1016/j.jhep.2018.12.004

Fig.7: In a syngeneic rat model of CCA, targeting CAF by navitoclax associates to a decreased lymphatic vascularization and lymph node metastasisation.

Fig.7:

(A) In Fischer 344 male rats transplanted with BDE-neu rat CCA cells, selective depletion of CAF by navitoclax was accompanied by a significant decrease in Lyve-1+ LEC without affecting CD31+ blood endothelial cells compared to untreated rats. Up-sided, representative images of CCA sections, with dual immunofluorescence for CD31 (red) and Lyve-1 (green), show the stark differences in lymphatic and blood vessels between navitoclax and vehicle groups. (B) Concomitantly, navitoclax led to a reduction in the number of lymph node metastases that was significant at the peritoneal region (p<0.05), and close to significance at the paraortic region (p=0.068). (n=6 for each group). Original magnification: 100x. **p<0.01 vs Vehicle, using two-tail t test.